NIAMS Clinical Trial Implementation Cooperative Agreement

Key facts

Copied from the official Grants.gov record. Last verified October 29, 2026.

Program name

NIAMS Clinical Trial Implementation Cooperative Agreement

Issuing agency

National Institutes of Health (Department of Health and Human Services)

Opportunity number

PAR-28-031

Funding type

Cooperative Agreement

Funding purpose

Health

Status

Forecasted

Application deadline

Forecasted · estimated close July 2, 2027 (agency estimate)

Agency estimates

Estimated posting: November 2, 2026. Estimated award date: April 3, 2028. Estimates can change.

Published award range

From $250,000

Expected number of awards

4

Cost sharing or match required

No

Eligible applicants (official categories)

• State governments
• County governments
• City or township governments
• Special district governments
• Independent school districts
• Public and State controlled institutions of higher education
• Native American tribal governments (Federally recognized)
• Public housing authorities/Indian housing authorities
• Native American tribal organizations (other than Federally recognized tribal governments)
• Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
• Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
• Private institutions of higher education
• For profit organizations other than small businesses
• Small businesses
• Others (see Additional Information on Eligibility)

Relevant to

Businesses and NonprofitsHow we determined this: Grants.gov eligibility includes small businesses or for-profit organizations. Grants.gov eligibility includes nonprofit organizations.

Geographic restrictions

None stated in structured data (federal opportunities are often nationwide). Check the eligibility details and full announcement for any limits.

Assistance Listing (CFDA)

93.846

Official source

View on Grants.gov ↗

Application URL

www.grants.gov/search-results-detail/362753 ↗Apply through Grants.gov (Workspace) using the application package on the official listing, unless the full announcement names a different submission system.

Source identifier

Grants.gov opportunity ID 362753 · Funding opportunity number PAR-28-031

Posted

June 10, 2026 · Source last updated June 10, 2026

Last verified

October 29, 2026 (against Grants.gov)

Data completeness

100% of key fields published by the source

Record confidence

mediumforecast — dates and amounts are agency estimates.

Eligibility details (from the agency)

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Description (from the official listing)

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for the Clinical Trial Cooperative Agreement Program within the mission areas of the institute. This Notice of Funding Opportunity (NOFO) solicits cooperative agreement applications for implementation of investigator-initiated, single or multi-site, interventional clinical trials (all trial phases). Investigators who have completed all necessary preparation (e.g., the trial design, protocol synopsis, data analysis plan, etc.) through other means may apply for a NIAMS Cooperative Agreement Clinical Trial. The first phase is designed to allow the investigators to prepare the final aspects needed to start the trial, (e.g., establishing the single IRB (sIRB), contracts and reliance agreements with sites, hiring of staff, etc.). Transition to the second phase to begin the trial is dependent upon completion of the phase 1 milestones proposed by the investigator and approved by NIAMS. Phase 1 projects that meet their milestones will be administratively considered by NIAMS and prioritized for transition to the second phase. NIAMS expects trials to be hypothesis-driven and have the potential for high clinical impact within the research mission of NIAMS.

Agency contact

National Institute of Arthritis and Musculoskeletal and Skin Diseases
NIAMS_NOFOs@mail.nih.gov